

Acute Pulmonary Embolism - A Clinical Review.

K. Manitha¹, G. Ravindra²

¹Assistant Professor, Department of Cardio Thoracic Surgery, Gandhi Medical College, Secunderabad, Telangana.

²Professor, Department of Cardio Thoracic Surgery, Gandhi Medical College, Secunderabad, Telangana.

Received: November 2016

Accepted: November 2016

Copyright: © the author(s), publisher. Annals of International Medical and Dental Research (AIMDR) is an Official Publication of "Society for Health Care & Research Development". It is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Acute pulmonary embolism is a life threatening condition with a high mortality rate. If diagnosed early, the patient outcome is better. Therefore, early assessment, diagnosis and appropriate treatment are a key to successful management of the patient. This article discusses two (2) cases of acute pulmonary embolism of different aetiologies and also undertakes a review of the literature with regards to classification systems, risk stratification, diagnostic tools and recent advances in management of pulmonary embolism.

Keywords: Acute pulmonary embolism, etiology, deep venous thrombosis, management

INTRODUCTION

Acute pulmonary embolism (PE) is an acute entrapment in pulmonary arteries of dislodged thrombus usually from deep veins of legs, pelvis or arms. It is life threatening and can result in right heart failure low cardiac output and sudden death.^[1] Due to its variable initial presentation the true incidence of PE is difficult to estimate.

Dr. John Gibbon^[2], designed cardiopulmonary bypass (CPB) after observing a patient of massive pulmonary embolism when he was a Research fellow in Massachusetts General Hospital.

Name & Address of Corresponding Author

Dr. K. Manitha
Assistant Professor,
Department of Cardio Thoracic Surgery,
Gandhi Medical College, Secunderabad, Telangana.

Studies published by De Monaco et al^[3] in 2008 and Wiener et al in 2011 both demonstrated significant increases in the incidence of PE while severity of illness decreased over this period of time. The authors postulated that over diagnosis explains the rapid rise in the incidence of PE because most of the cases are clinically unimportant and non- fatal. Over diagnosis is important to recognise because treatment of PE has its own risks, especially in whom PE is unimportant.

MATERIALS AND METHODS

Material is gathered from Kirklin, Pubmed, Google, Journal of clinical trial results, case reports. Studies from peer-reviewed sources are included.

CASE REVIEW

We report two patients who presented with acute massive pulmonary embolism, the mode of presentation, haemodynamics and etiology of both the cases is different.

Case 1 – 48 year old female patient who is a known case of carcinoma uterus, post-hysterectomy and radiotherapy, presently on chemotherapy admitted for staging laparotomy. On third post-operative day, patient developed shortness of breath with a respiratory rate of 54/min, bradycardia, raised JVP. In view of her previous history and her clinical presentation, acute PE was suspected. She was started on intravenous infusion of UFH, while awaiting diagnosis. Patient underwent emergency CTPA, which confirmed the diagnosis. But, after 24 hours patient succumbed. Thrombolysis was deferred in view of her medical history fearing bleeding.

Case 2 – A 44 year old female patient was referred from a primary center with a history of swelling of the right lower limb for two weeks, with a recent onset of dyspnoea with increasing severity. On admission, suspecting PE, CTPA was done which showed massive embolism extending from main pulmonary artery into lobar branches on the left side with evidence of multiple infarcts in the left lung. Doppler of lower extremities revealed proximal VTE. As the patient presented late in the course of disease, and was also hemodynamically stable she was started on anti-coagulation with unfractionated heparin. But patient continued to deteriorate. Suspecting that she was throwing emboli from lower extremities an IVC filter was planned. As the patient

and attendants were unwilling, the procedure was delayed during which time we lost the patient.

DISCUSSION

The common cause in most cases of pulmonary thromboembolism is detached venous thrombi from the lower limbs and rarely upper limbs, passing through the right heart and entering the pulmonary arteries as a single thrombus or as a fragmented smaller thrombi. Majority lodge in the lower lobes, slightly more in the right than left lung. Shortly after reaching the lungs these emboli get coated with layer of platelets and thrombin. In addition to causing pulmonary arterial obstruction, the platelets on thrombus release vasoactive agents, which elevate pulmonary vascular resistance (RP). Alveolar dead space increases as a result of redistribution of blood flow and V/Q mismatch occurs. Right ventricular (RV) after load increases, RV pressure rises. This results in RV dilatation, ischemia and dysfunction. Increased RP results in reduced RV stroke volume and left ventricular preload. Reduction in preload leads to systemic hypotension and reduction coronary blood flow. This markedly reduces left ventricular stroke volume. If a patent foramen ovale or ASD is present, right to left shunting of blood and severe hypoxemia may occur. Paradoxical embolization may also occur.

Rudolf Virchow^[5] has first described the pathophysiology of venous thromboembolism. The Virchow's triad describes the factors contributing to the formation of venous thrombi consisting of hypercoagulability, stasis and endothelial injury. Risk factors for venous thromboembolism are listed in [Table 1].

Table 1: Risk factors for venous thromboembolism.

Table 1. Risk Factors for Venous Thromboembolism (VTE)
<i>Primary</i>
• Idiopathic
• Age > 65 years
• Thrombophilia or inherited hypercoagulable state
• Obesity
• Previous VTE
<i>Secondary/acquired</i>
• Immobility or paralysis
• Trauma especially major limb trauma
• Recent surgery
• Pregnancy
• Oral contraceptive therapy
• Cancer
• Major medical illness (myocardial infarction, stroke, etc.)

Venous stasis is a prominent contributing factor for the formation of deep venous thrombosis (DVT)^[6]. Thrombus formation occurs in venous valve pockets due to a combination of slow flow and endothelial

inflammation caused by blood flow turbulence within these pockets. These factors when combined with prolonged immobility can increase risk of deep venous thrombosis^[7]. Clots formed in deep veins behind or proximal to knee are more likely to result in fatal PE, than are clots distal to the popliteal vein (Kearon 2003)^[7]. This is probably true because thrombi that originate in calf are small and thrombi that embolise from proximal leg veins are usually large.

Pulmonary emboli can be detected in approximately 50% of patients with documented DVT (Hull, 1983; Plate, 1985). Symptomatic DVT is seen in 70% of patients with documented and diagnosed PE (Hirsch and Hoak, 1996). The possibility of PE due to causes other than lower limbs has been suggested by Ogren 2005.

The cause of DVT is multifactorial. Molecular factors include inherited or acquired hypercoagulable states^[8]. Risk factors being major surgery, advanced age, prior VTE or family history, cancer major trauma, spinal cord injury, pregnancy, chronic medical illness and oral contraceptives.

Classification:

Pulmonary embolism is classified as minor, major, massive^[1]. Massive PE may be defined as acute PE with sustained hypotension, pulselessness, or profound bradycardia with symptoms of shock. Major PE is defined as acute PE without systemic hypotension but with either RV dysfunction or elevated troponin I or T indicative of myocardial injury. Minor PE is defined as acute PE without clinical markers that define massive or major PE. RV dysfunction may be defined as RV systolic function on echocardiography^[17], RV dilatation RV/LV diameter >1, and ECG changes.

CLINICAL PRESENTATION

Clinical presentation of PE is variable and nonspecific. Classically patients present with atypical chest pain, dyspnoea and haemoptysis. But these symptoms are present in less than 20% of patients as the PIOPED study showed.

The haemodynamic consequences of PE depend not only on the size and number of emboli, but also on the pre-existing cardiac and respiratory status (European Society of cardiology, 2000). Acute PE causes both respiratory and cardiac compromise. Respiratory function is compromised by obstruction of pulmonary arteries, which elevates pulmonary vascular resistance. The increase in alveolar dead space and alteration in ventilation perfusion mismatch impair gas exchange. Cardiac failure results from increased wall stress, cardiac ischemia RV dysfunction. Significant RV damage can produce elevated troponin levels (Meyer 2000).




Figure 1: ?????????

DIAGNOSIS

Pulmonary embolism can be a severe and fatal disease but difficult to diagnose as the signs and symptoms are nonspecific. But the investigations used to diagnose PE at times may over diagnose the condition leading to potential harm and unnecessary expense.

Therefore, a few variables have been combined to form prediction rules to predict the probability of PE. The most commonly used are WELLS SCORE and revised GENEVA RULES [Tables 2 & 3].

Table 2: Wells Score

Variable	Points
Clinical Signs and symptoms of deep venous thrombosis(DVT) (Leg swelling and tenderness)	3
Alternate diagnosis less likely than pulmonary embolism	3
Heart rate more than 100 bpm	1.5
Immobilisation or surgery in the previous 4 weeks	1.5
Previous DVT/PE	1.5
Haemoptysis	1
Malignancy	1
Calculation of Clinical Probability	Total
Low	<2
Intermediate	2 to 6
High	>6

Table 3: Revised Geneva Score

Risk Factors	Points
Age >65 years	1
Previous DVT or PE	3
Surgery or fracture of lower limbs within the past month	2
Active Malignancy	2
Symptoms	

Unilateral lower limb pain	3
Haemoptysis	2
Clinical or physical exam signs	
Heart rate 75 to 94 BPM	3
Heart rate >95BPM	5
Low limb pain on deep venous palpation and unilateral oedema	4
Clinical Probability	Total
Low	0 to 3
Intermediate	4 to 10
High	>10




Figure 2: ?????????




Figure 4: ?????????

CT SCAN:

Table 4: Imaging rationality

Clinical Situation	Basis for Imaging Action (Reference)
Immediate CT Hemodynamically unstable, with suspected PE* High pretest probability of PE	Risks of inaction outweigh risks of CT Incidence of PE 19%-28% even with a D-dimer level <500 ng/mL (7, 74)
Defer CT until after D-dimer result Intermediate pretest probability Low pretest probability and PERC > 0	Low incidence of PE (<1.1%) if D-dimer level <500 ng/mL (41-43)
No CT or D-dimer test Low pretest probability and PERC = 0	Incidence of PE <1% (47)
Begin with lower-extremity venous ultrasonography Patients with symptoms of DVT and PE	Similar treatment will be pursued without exposing the patient to the risks of radiation or intravenous contrast

CT = computed tomography; DVT = deep venous thrombosis; PE = pulmonary embolism; PERC = Pulmonary Embolism Rule-Out Criteria.

* Hemodynamic instability may make transport for imaging problematic. Supportive measures or empirical anticoagulation until imaging can be obtained may be required.

Arterial blood gas analysis:

It may show respiratory alkalosis and hypoxaemia.

Echo cardiogram:

Though not diagnostic of PE, it can be helpful in determining the risk of mortality or adverse outcomes. It helps in diagnosing RV dysfunction and failure. It may also be used to visualise patent foramen ovale in cases of paradoxical systemic embolism and also any thrombi. The response to treatment can be evaluated by the improvement of RV function.

Ventilation and perfusion scan:

It is less expensive and less invasive than pulmonary angiography. A perfusion defect without a corresponding ventilation defect has a high probability of PE. A perfusion defect with matched ventilation has a low probability of PE. Matched perfusion defects corresponding to those on chest X-ray as in COPD have an intermediate probability.

Pulmonary angiography:

It was the gold standard for diagnosing PE. But the cost, requirement of qualified personnel to do the procedure, the risks involved in the procedure and the availability of less expensive, non-invasive methods made this procedure obsolete.

CTPA:

It is being extensively used in the diagnosis of PE. The condition is seen as a filling defect. Radiation is a drawback of this investigation.

MR Angiography:

It is being used in situations where CTPA is contraindicated as in contrast allergies and in pregnant women.

D Dimers:

This is not a specific test for PE, but a normal or negative D dimer in a low probability situation excludes PE.

Cardiac Troponins:

Presence of cardiac enzymes along with PE was associated with adverse outcome as their presence indicate RV stress and failure. Along with H-FABP, and BNP these indicate RV strain and dysfunction.

Venous duplex ultra sound:

Along with compressibility this investigation is used to diagnose DVT in peripheral limbs. In a non-diagnostic V/Q scan a negative venous duplex rule out PE. As such a venous ultra sound is recommended in situations where there is low probability of PE.

TREATMENT

Anticoagulation is the mainstay of treatment for acute PE, the objectives being prevention of thrombus extension and recurrence of VTE. Rapid anticoagulation can be achieved by using parenteral anti-coagulants as UFH, LMWH, or fondaparinux. In cases of high probability and while awaiting confirmation this therapy may be considered in the absence of contraindications.

Thrombolysis:

Achieves clot lysis more rapidly than anticoagulation. It reduces pulmonary vascular resistance, improves pulmonary perfusion, haemodynamics and gas exchange. Rapid clot reduction also reduces the risk of chronic pulmonary hypertension.

Pulmonary embolectomy:

It is used to relieve acute obstruction in emergency situations when thrombolysis is contra indicated or not practical. Mortality with this procedure is high and can be associated with complications like ARDS, mediastinitis, ARF, and severe neurological sequelae.

Massive PE patient usually presents in emergency block in a decompensate state. High clinical

suspicion is warranted. After stabilisation and confirmation of diagnosis thrombolysis either systemic or catheter directed and/or mechanical thrombectomy percutaneously or surgical embolectomy are preferred.

Intravenous thrombolysis has been shown to reduce risk of death and recurrent PE significantly but GI bleeds and intracranial or retroperitoneal bleeds are frequent than warranted. Unfractionated heparin should be used for anti-coagulation.

Catheter directed thrombolysis and mechanical thrombectomy has been recommended in patients with proximal PE with absolute contraindications to systemic thrombolysis or surgical embolectomy, or those who failed thrombolytic therapy. Another device used to treat massive PE is the Ekosonic ultrasound assisted thrombolysis infusion device. A recent publication has shown that ultrasound assisted thrombolysis resulted in improvement of clinical symptoms and RV dysfunction without major bleeding complications.

The main stay of treatment in for acute PE in nonmassive i.e., minor and major PE is systemic anticoagulation. The standard regimen is a course of LMWH, or Fondaparinux for 5 days with VKA started on third day of anticoagulation to maintain a INR between 2 and 3. UFH has to be given as a continuous infusion, and bleeding complications are also more. Compared to LMWH the incidence of HIT is high with UFH.

Direct thrombin inhibitors as hirudin, argatroban, melagatran, ximelagatran are not first line of treatment in PE, but are being investigated.

Inferior vena cava filters:

These filters function to prevent large emboli from lower extremities from reaching lungs. Candidates for IVC filter placement are those who have DVT and have contraindications to anticoagulation, recurrence despite adequate anticoagulation, inability to achieve or maintain therapeutic anti coagulation. Many trials have been done like PREPIC, DENALI, but there is no uniform consensus on usage of IVC filters in PE. Use is determined by case to case basis.

Long-term treatment:

The aim of long term treatment is to prevent fatal and nonfatal recurrence of VTE. VKA's are given to maintain INR at 2-3. They remain the treatment of choice for long term. The duration depends on the risk of recurrent VTE after discontinuation, patient's demographics, and the risk of bleeding.

CONCLUSION

Pulmonary embolism is a common and fatal disease. The two cases discussed above emphasize the fact. Early and correct diagnosis is important. Diagnosis is difficult as the presentations are varied and

nonspecific. A high degree of clinical suspicion is necessary to come to an early and accurate diagnosis. At the same time over diagnosis is also harmful subjecting the patients to unnecessary investigations, which in themselves are harmful. The American college of physicians has issued the best practice advice for evaluation of patients with pulmonary embolism. Institution of appropriate treatment saves many lives. The corner stone of therapy remains anticoagulation with Heparin. Surgical intervention is reserved in those who are unstable and anticoagulation and/or thrombolysis is contraindicated. Newer strategies, drugs and devices to treat PE continue to emerge.

REFERENCES

1. Kirklin et al. Diseases of pulmonary arteries, cardiac surgery 3rd edition, Churchill Livingstone, Philadelphia. 1993; 1902-1903.
2. Clowes GHA., Jr. Bypass of the heart and lungs with an extracorporeal circulation. In: Gibbon JH, Sabiston DC, Spencer FC, editors. Surgery of the chest. 2nd ed. Philadelphia: Saunders; 1969.
3. DeMonaco NA, Dang Q, Kapoor WN, Ragni MV. Pulmonary embolism incidence is increasing with use of spiral computed tomography. Am J Med. 2008;121(7):611-617.
4. Virchow R. Cell Pathology, 1859 Special Edition. London: John Churchill. 1978:204-207.
5. DeWalt DA, Pincus T. The legacies of Rudolf Virchow: cellular medicine in the 20th century and social medicine in the 21st century. Isr Med Assoc J. 2003;5:395-397. [PubMed]
6. Natural History of Venous Thromboembolism Clive Kearon, MB, MRCPI, FRCPC, PhD
7. Schick P, Schick B. Hypercoagulability—hereditary thrombophilia and lupus anticoagulants associated with venous thrombosis and emboli workshop. 2013. <http://emedicine.medscape.com/article/211039-workup>.
8. Baarslag HJ, Koopman MMW, Reekers JA, van Beek EJR. Diagnosis and management of deep vein thrombosis of the upper extremity: a review. Eur Radiol. 2004;14(7):1263-1274.
9. Miniati M, Prediletto R, Formichi B et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 1999;159(3):864-871.
10. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995; 345 (8961): 1326-1330.
11. Le Gal G, Righini M, Roy P-M, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165-171
12. Klok FA, Kruisman E, Spaan J, et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. J Thromb Haemost. 2008;6(1):40-44.
13. Runyon MS, Richman PB, Kline JA. Emergency medicine practitioner knowledge and use of decision rules for the evaluation of patients with suspected pulmonary embolism: variations by practice setting and training level. Acad Emerg Med. 2007;14(1):53-57
14. Stein PD, Goldhaber SZ, Henry JW. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest J. 1995;107(1):139-143.
15. Kabrhel C, Mark Courtney D, Camargo CA, et al. Factors associated with positive d-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. 2010; 17(6):589-597.
16. Rodger MA, Carrier M, Jones GN, et al. Diagnostic value of arterial blood gas measurement in suspected pulmonary

- embolism. *Am J Respir Crit Care Med.* 2000;162(6):2105–2108.
17. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. *Circulation.* 2007;116(4):427–433.
 18. Rodger M, Makropoulos D, Turek M, et al. Diagnostic value of the electrocardiogram in suspected pulmonary embolism. *Am J Cardiol.* 2000;86(7):807–809, A10.
 19. Goldhaber SZ. Echocardiography in the management of pulmonary embolism. *Ann Intern Med.* 2002;136(9):691–700
 20. Oudkerk M, van Beek EJR, Wielopolski P, et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. *Lancet.* 2002;359(9318):1643–1647
 21. Stein PD, Kayali F, Olson RE. Trends in the use of diagnostic imaging in patients hospitalized with acute pulmonary embolism. *Am J Cardiol.* 2004;93(10):1316–1317.
 22. Turkstra F, Kuijter PM, van Beek EJ, Brandjes DP, Jan W, Buller HR. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. *Ann Intern Med.* 1997;126(10):775–781.
 23. Kristiansen A, Brandt L, Agoritsas T, et al. Applying new strategies for the national adaptation, updating and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the American College of Chest Physicians Evidence-based guidelines on antithrombotic therapy and the prevention of thrombosis, 9th edition. *Chest.* 2014;146(3):735–761.
 24. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. *Ann Intern Med.* 2004;140(3):175–183.
 25. Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med.* 2003;349(18):1695–1702.
 26. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood.* 2005;106(8):2710–2715.
 27. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2012;141(2_Suppl):e419S–e494S.
 28. Van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost.* 2014;12(3):320–328
 29. Harikrishnan P, Palaniswamy C, Aronow WS. Update on pharmacologic therapy for pulmonary embolism. *J Cardiovasc Pharmacol Ther.* 2014;19(2):159–169.
 30. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med.* 2014;370(15):1402–1411.
 31. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. *J Thromb Haemost.* 2014;12(4):459–468.
 32. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. *Circulation.* 2004;110(6):744–749.
 33. Tapson VF. Treatment of pulmonary embolism: anti-coagulation, thrombolytic therapy, and complications of therapy. *Crit Care Clin.* 2011;27(4):825–839, vi.
 34. Kuo WT. Endovascular therapy for acute pulmonary embolism. *J Vasc Interv Radiol.* 2012;23(2):167–179.e4.
 35. Chamsuddin A, Nazzal L, Kang B, et al. Catheter-directed thrombolysis with the Endowave system in the treatment of acute massive pulmonary embolism: a retrospective multicenter case series. *J Vasc Interv Radiol.* 2008;19(3):372–376.
 36. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. *J Vasc Interv Radiol.* 2009;20(11):1431–1440.
 37. Lin PH, Annambhotla S, Bechara CF, et al. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. *Vascular.* 2009;17(Suppl3):S137–S147.
 38. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation.* 2014;129(4):479–486.
 39. Jain SKA, Patel B, David W, Jazrawi A, Alexander P. Unloading of right ventricle and clinical improvement after ultrasound-accelerated thrombolysis in patients with submassive pulmonary embolism. *Case Rep Med.* 2014;2014.
 40. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med.* 1998;338(7):409–415.
 41. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. *Circulation.* 2005;112(3):416–422.
 42. Stavropoulos SW, Sing RF, Elmasri F, et al. The DENALI trial: an interim analysis of a prospective, multicenter study of the Denali retrievable inferior vena cava filter. *J Vasc Interv Radiol.* 2014;25(10):1497–1505.
 43. Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. *Cochrane Database Syst Rev.* 2010;(2):CD006212.

How to cite this article: Manitha K, Ravindra G. Acute Pulmonary Embolism - A Clinical Review. *Ann. Int. Med. Den. Res.* 2017; 3(1):SG08-SG13.

Source of Support: Nil, **Conflict of Interest:** None declared